Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
19.84
+1.18 (6.32%)
May 29, 2025, 4:00 PM - Market closed
Celldex Therapeutics Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Celldex Therapeutics stock ranges from a low of $31 to a high of $70. The average analyst price target of $50 forecasts a 152.02% increase in the stock price over the next year.
Price Target: $50.00 (+152.02%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $44 → $38 | Strong Buy | Maintains | $44 → $38 | +91.53% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $31 | Hold | Maintains | $36 → $31 | +56.25% | May 9, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $46 → $43 | Buy | Maintains | $46 → $43 | +116.73% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $50 | Strong Buy | Maintains | $80 → $50 | +152.02% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +303.23% | May 6, 2025 |
Financial Forecast
Revenue This Year
4.19M
from 7.02M
Decreased by -40.36%
Revenue Next Year
3.03M
from 4.19M
Decreased by -27.75%
EPS This Year
-3.50
from -2.45
EPS Next Year
-4.07
from -3.50
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.6M | 12.6M | 104.1M | ||
| Avg | 4.2M | 3.0M | 36.9M | ||
| Low | 681,100 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.5% | 200.9% | 3,342.6% | ||
| Avg | -40.4% | -27.8% | 1,120.5% | ||
| Low | -90.3% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.19 | -3.01 | -2.77 | ||
| Avg | -3.50 | -4.07 | -3.75 | ||
| Low | -3.84 | -5.07 | -4.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.